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Heparan sulfate proteoglycans are important modulators of growth factor signaling in a variety of patterning processes. Secreted growth
factors that play critical roles in angiogenesis bind to heparan sulfate, and this association is affected by 6-O-sulfation of the heparan sulfate
chains. Addition of 6-O-sulfate is catalyzed by a family of sulfotransferases (HS6STs), and genetic manipulation of their function permits an
assessment of their contribution to vascular assembly. We report on the biochemical activity and expression patterns of two zebrafish HS6ST
genes. In situ hybridization reveals dynamic and distinct expression patterns of these two genes during development. Structural analysis of
heparan sulfate from wild-type and morpholino antisense Fknockdown_ embryos suggests that HS6ST-1 and HS6ST-2 have similar
biochemical activity. HS6ST-2, but not HS6ST-1, morphants exhibit abnormalities in the branching morphogenesis of the caudal vein during
embryonic development of the zebrafish. Our finding that HS6ST-2 is required for the branching morphogenesis of the caudal vein is the first
in vivo evidence for an essential role of a gene encoding a heparan sulfate modifying enzyme in vertebrate angiogenesis. Our analysis of two
zebrafish HS6ST genes suggests that a wide range of biological processes may be regulated by an array of sulfation-modifying enzymes in
the vertebrate genome.
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Heparan sulfate proteoglycans (HSPGs) are present on
the cell surface and in the extracellular matrix and play
important roles in a variety of biological processes such as
cell adhesion, wound healing and microbial pathogenesis0012-1606/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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Stopford Building, Oxford Road, Manchester, M13 9PT, UK.(Rosenberg et al., 1997; Bernfield et al., 1999; Rapraeger,
2001). Each heparan sulfate chain attached to the protein
core of an HSPG is composed of alternating d-glucuronic
acid (GlcA) and N-acetyl-d-glucosamine units. N-sulfation
of a proportion of the disaccharides occurs in blocks often
referred to as S-domains. Within the S-domains other
modifications take place, such as epimerization of GlcA to
l-iduronic acid, sulfation at the 2-O position of uronic
acid, or the 3-O position and the 6-O position of
glucosamine. The sulfation pattern within the S-domains,
as well as their length and spacing, contribute to the
structural heterogeneity of heparan sulfate and may create
specific binding sites for protein ligands (Esko and
Selleck, 2002).84 (2005) 364 – 376
HS6ST-1 MO #1: 5V-TCCAGTGAGGAGGTTCATGTGT-
TAC-3V
HS6ST-1 MO #2: 5V-GTTGACTGTTTTTTAGGGT-
GTCTCC-3V
HS6ST-2 MO #1: 5V-GATTTCCCATCCATCTTCTC-
GCTGG-3V
HS6ST-2 MO #2: 5V-AGTGAAAGCATTACTCGGTT-
GTGCG-3V
VEGF-A MO: 5V-GTATCAAATAAACAACCAAGTTCAT-
3V
VEGF-A MOd4 (four-base mismatches are in lower-case):
5V-GTAaCAAtTAAACAACCAtGTTgAT-3V
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often essential for modulating ligand-receptor binding and
can influence the outcome of downstream signaling events
(Perrimon and Bernfield, 2000; Esko and Selleck, 2002;
Nakato and Kimata, 2002). The developmental abnormal-
ities found in mutants deficient in the function of heparan
sulfate biosynthetic enzymes have demonstrated the impor-
tance of heparan sulfate fine structure in regulating a variety
of patterning and morphogenetic events in many organisms.
For example, mice homozygous for a gene trap mutation in
Hs2st show renal agenesis, eye and skeletal defects (Bullock
et al., 1998). RNA interference of the Drosophila HS6ST
gene produces defective branching in the tracheal system, a
developmental system that shares many of the signaling
components required for vertebrate angiogenesis (Kami-
mura et al., 2001).
In vitro studies have implicated heparan sulfate 6-O
sulfation as a critical regulatory step in vessel formation. For
example, 6-O desulfated heparin abolishes the amplifying
effect of heparin on FGF-2 activation of FGFR-1 signaling
and also inhibits FGF-2 induced angiogenesis (Lundin et al.,
2000). The specific arrangement of 6-O-sulfated disacchar-
ide units within heparan sulfate plays an important role in
the binding of Endostatin, a peptide inhibitor of angio-
genesis that requires heparan sulfate for its anti-angiogenic
effect (Blackhall et al., 2003). While these in vitro studies
suggest an important role for 6-O modification of heparan
sulfate in vascular assembly, the functional requirement for
this structural modification of HS in vivo is not known. We
are using the zebrafish as a vertebrate model system to
address the role of 6-O sulfation in vascular development, a
highly conserved vertebrate developmental process (Roman
and Weinstein, 2000; Weinstein, 2002). In contrast to
mammals, passive diffusion of oxygen can sustain survival
of zebrafish embryos without functional vasculature. This
advantage permits the identification of genes essential for
different stages of vascular development.
In this study, we have examined the function and
expression of two zebrafish heparan sulfate 6-O sulfo-
transferase (HS6ST) genes, HS6ST-1 and HS6ST-2. The
HS6ST-2 gene was originally identified from a morpho-
lino-based screen for genes affecting vascular assembly
and function in zebrafish, and its role in muscle develop-
ment has been previously characterized by Bink et al.
(2003). Using morpholino anti-sense oligonucleotides to
inhibit HS6ST-1 and -2 function, we show that these two
proteins are required for normal patterns of 6-O sulfation.
HS6ST-1 and HS6ST-2 display distinct expression patterns
in vivo. HS6ST-2 is expressed in the region around the
caudal vein, and HS6ST-2 morphant embryos show defects
in the branching morphogenesis of the caudal vein, defects
which were not observed in HS6ST-1 morphant embryos.
The finding that HS6ST-2 is essential for the branching
morphogenesis of the caudal vein in zebrafish is the first
evidence for an in vivo role of a HS6ST in vascular
development of a vertebrate system.Materials and methods
Morpholino sequences and injections
The HS6ST-1 and HS6ST-2 morpholino phosphorodia-
midate oligonucleotides (morpholinos), from Gene Tools,
LLC, have the following sequences:All were designed against the corresponding cDNA (see
GenBank accession numbers below). All morpholinos
were prepared and injected as previously described
(Nasevicius and Ekker, 2000). HS6ST-2 MO #1 is
identical to the HS6ST MO #1 described by Bink et al.
(2003) and HS6ST-2 MO #2 is shifted one base 5Vof their
second HS6ST-2 targeted morpholino. VEGF-A morpho-
linos are from Nasevicius et al. (2000).
Raising and staging embryos
Embryos were raised at 29-C. Zebrafish embryos were
staged using standard morphological criteria (Kimmel et al.,
1995) prior to fixation and analysis to compensate for any
observed developmental delay.
Microangiography analysis
For microangiography analysis, tetramethylrhodamine
isothiocyanate (TRITC)-dextran dye was dissolved in 0.3 
Danieau buffer (58 mMNaCl, 0.7 mMKCl, 0.4 mMMgSO4,
0.6 mM (CaNO3)2, 5.0 mM HEPES pH 7.6) at 20 mg/ml and
was microinjected into the common cardinal vein of Tg(fli-
1:EGFP) embryos as previously described (Nasevicius et al.,
2000). The fli-1:EGFP-labeled vasculature and the micro-
angiograms were visualized using the FITC and the TRITC
filter sets as previously described (Finley et al., 2001).
Cloning of zebrafish HS6ST-1 and HS6ST-2
The full-length coding sequence for zebrafish HS6ST-1
and HS6ST-2 was determined by standard sequencing of
EST clones obtained from Incyte Genomics. The cDNA
sequences were submitted to GenBank (HS6ST-1:
AY575770; HS6ST-2: AY575769).
Fig. 1. Identification of zebrafish HS6ST-1 and HS6ST-2 genes. (A)
Deduced amino acid sequence of zebrafish HS6ST-2 (A) and zebrafish
HS6ST-1 (B) genes. The putative PAPS binding sites are underlined. (C)
Phylogenetic tree of vertebrate HS6ST proteins assembled using CLUSTAL
analysis (Macvector 7.2.3 software). The value at each branch denotes the
mean number of differences per residue along each branch (Thompson et
al., 1994). Human HS6ST-2 S is an alternate isoform of HS6ST-2 (Habuchi
et al., 2003).
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A SpeI site was introduced at the 5Vand the 3Vends of the
zebrafish HS6ST-1 and HS6ST-2 coding sequence by PCR,
using the EST clones as the DNA template. The PCR
fragment was subsequently subcloned into the SpeI site of
the FRM expression construct (Gibbs and Schmale, 2000).
DNA-based rescue of morpholino-induced defects was
conducted using the methods essentially as previously
described for syndecan-2 (Chen et al., 2004). The solution
of the test DNA construct mixed with FRM-DsRed
expression construct was injected into 1-cell embryos at
the interface between the yolk and the blastomere to ensure
uniform mosaic distribution (Finley et al., 2001). The FRM-
DsRed expression construct is used as a lineage tracer to
facilitate the selection of embryos showing mostly uniform
mosaic expression.
Preparation and HPLC analysis of heparan sulfate
disaccharides
This protocol was adapted from Toyoda et al. (2000) and
Ledin et al. (Unpublished, Uppsala University, Sweden).
Samples of 100, 48 hpf dechorionated zebrafish were
washed in distilled water and lyophilized, then resuspended
in 0.5 ml 50 mM Tris/HCl pH 8, 1 mM CaCl2, 1% Triton-
X100. The samples were sonicated three times for 30 s at
4–5 W before removal of a fraction of material for protein
estimation (Pierce BCA Assay). Samples were then digested
with 0.8 mg/ml protease for 16 h at 55-C, heat inactivated at
96-C for 5 min, then incubated 2 h at 37-C with 1 Al 1 M
MgCl2 and 0.5 Al (168.5 U) benzonase. NaCl was added to
0.1 M and insoluble material removed by microcentrifuga-
tion for 10 min at 16,000g. The solution was applied on a
Vivapure Mini D membrane (Sartorius AG, Germany),
which had been equilibrated with sodium phosphate buffer
(pH 6.0) containing 0.15 M NaCl. The fractions eluted with
1.0 M NaCl in the same buffer were collected, desalted with
Biomax-5 (Millipore, Billerica, MA) filtration column,
lyophilized and resuspended in 15 Al 0.03 M sodium acetate
buffer (pH 7.0) with 3.33 mM calcium acetate, 0.33 mIU
heparinase, 0.33 mIU heparitinase II and 0.33 mIU
heparitinase I (Seikagaku America, East Falmouth, MA).
The mixture was incubated at 37-C for 16 h, lyophilized and
resuspended in 12 Al water to load onto the HPLC. HPLC
conditions were as Toyoda et al., 2000.
In situ hybridization
A BglII site was introduced at the 5Vand the 3Vends of
the zebrafish HS6ST-2 coding sequence by PCR, and the
DNA fragment was subcloned into the BglII site of T3TS
(Hyatt and Ekker, 1999). The plasmid was linearized with
SpeI and T3 polymerase was used for DIG-labelled anti-
sense RNA synthesis. The PCR fragment containing the
open reading frame of HS6ST-1 was subcloned into theTOPO vector (Invitrogen). The plasmid was linearized with
SpeI, and T7 polymerase was used for DIG-labelled anti-
sense RNA synthesis. DIG-labelled probes were synthesized
using the in vitro DIG labelling kit (Roche). The in situ
hybridization procedure was performed essentially as
described (Jowett, 1999).Results
In our ongoing morpholino-based screen to identify
novel genes essential for vascular development in the
zebrafish, Danio rerio, we characterized vascular defects
in embryos injected with morpholinos against a gene
fragment with similarity to vertebrate HS6ST proteins.
Upon full sequencing of the target cDNA (Fig. 1A) and
subsequent phylogenetic analysis (Fig. 1C), the gene target
was later identified as a zebrafish HS6ST-2 family member.
From the zebrafish EST database, one other HS6ST-related
gene was identified. Sequence (Fig. 1B) and phylogenetic
analysis (Fig. 1C) of the full-length coding sequence for this
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HS6ST-1 family member. We have conducted subsequent
analyses of the EST and genomic databases, and we have
identified fragments of sequence that code for possibly two
additional members of the zebrafish HS6ST gene family;
sequence coverage is, however, not sufficient to unambig-
uously assign likely orthology (data not shown).
The embryonic expression pattern of HS6ST-1 is distinct
from that of HS6ST-2 in zebrafish
To determine whether zebrafish HS6ST-1 and HS6ST-2
might have distinct biological roles, in situ hybridization
was conducted to compare spatial expression patterns
during development. A previous report by Bink et al.
(2003) demonstrated expression of HS6ST-2 in the brain
during somitogenesis and at 24 h post-fertilization (hpf) and
also in the fin buds at 48 hpf (Bink et al., 2003). Here, we
show that expression of HS6ST-2 is also detected in the
caudal wave of maturing somites from the 4-somite stage to
the 18 somite-stage (arrowheads in Figs. 2A–C and data not
shown). At the 22-somite stage, HS6ST-2 is detected in a
stripe of cells in ventral medial somites (Fig. 2D) and
persists through 24 hpf (Fig. 2E). A transverse section
through the caudal region of an embryo at 24 hpf indicates
expression of HS6ST-2 in the ventral medial somites and
cells surrounding the vascular structures of the dorsal aorta
and caudal vein in the tail (area of expression outlined by
dash lines in Fig. 2F).
Similar to HS6ST-2 (Fig. 2E), HS6ST-1 is also strongly
expressed in the eyes during somitogenesis (Figs. 2G–H).
In contrast to HS6ST-2, localized expression of HS6ST-1
mRNA in the brain is detected during somitogenesis, at 24
hpf and 33 hpf (Figs. 2I–K), and its expression is not
detected in the vasculature.
Analysis of heparan sulfate composition of HS6ST
morphants
To determine if HS6ST-1 and HS6ST-2 function affects
the structural modifications of heparan sulfate in vivo,
glycosaminoglycans were isolated from wild-type, buffer-
injected and morpholino-injected embryos. The partially
purified heparan sulfate was digested with heparin lyases
into disaccharides. The disaccharides were then separated
by reverse phase ion pair HPLC and labeled with post-
column fluorescent derivatization. The peaks were identi-
fied by their elution time compared to that of known
heparan sulfate disaccharide standards. Six disaccharide
species, including three 6-O sulfated disaccharides, DUA-
GlcNAc6S, DUA-GlcNS6S and DUA2S-GlcNS6S, (see
Fig. 3 legend for key to abbreviations) were present
in wild-type, buffer-injected, and morpholino-injected
embryos (Fig. 3, data not shown). Two of the three 6-O
sulfated disaccharides, DUA-GlcNAc6S and DUA-
GlcNS6S (peaks 3 and 4, Fig. 3B), were significantlyreduced in both HS6ST-1 MO- and HS6ST-2 MO-injected
embryos compared to wild-type embryos (see Table 1).
The relatively modest changes observed with morpholino
knockdown of either HS6ST-1 or HS6ST-2 are possibly
due to functional redundancy between HS6ST genes in
zebrafish, of which only one was targeted at a time. When
both HS6ST-1 and HS6ST-2 genes were simultaneously
targeted using a reduced dosage inhibition protocol to
allow embryo viability, there was no additional decrease in
the 6-O-sulfated disaccharides (data not shown). This
result suggests that there are other HS6ST genes in the
zebrafish that may be able to compensate for the remaining
6-O sulfotransferase function. The limited effects of the
morpholinos may also be attributed to the low doses that
were used to avoid any non-specific toxicity. There was no
change in HS-derived disaccharides from buffer-injected
embryos compared to wild-type controls indicating the
changes observed in heparan sulfate composition were not
a result of stress to the embryo due to the injection (Table
1). These results suggest that both HS6ST-1 and HS6ST-2
can sulfate similar disaccharide species, although these
disaccharides may be present within a different oligosac-
charide sequence, since the disaccharide profiling does not
provide information concerning the structural context of
any given disaccharide.
HS6ST-2 MO-injected embryos showed defective
morphogenesis of the caudal vein
In our morpholino-based screen, an EGFP transgenic line
(fli-1:EGFP) was used to assess vascular development. In
Tg(fli-1:EGFP) embryos, the fli-1 promoter drives the ex-
pression of the EGFP reporter in endothelial cells that line
the blood vessels (Lawson and Weinstein, 2002). At 24 hpf,
no apparent vascular defects were observed in HS6ST-2
MO-injected embryos. Beginning around 30 hpf, however,
HS6ST-2 MO-injected Tg(fli-1:EGFP) embryos showed
defective formation of the venous plexus, the network of
microvessels derived from the caudal vein (CV) (Fig. 4). In
the less severe case, HS6ST-2 MO-injected embryos
displayed reduced branching of the CV. Instead of the fine
meshwork of the CV observed in uninjected wild-type
embryos, HS6ST-2 MO-injected embryos exhibited the
formation of large loops in the CV plexus (arrowheads in
Fig. 4C). In the more severe case, HS6ST-2 MO-injected
embryos showed a lack of branching and instead formed
disorganized and over-lumenized vessels in place of the
venous plexus (arrowheads in Fig. 4E). In contrast, no vas-
cular defects were observed in embryos injected with the
HS6ST-1 morpholino at a dose where a change in the 6-O
sulfation profile was observed (Fig. 3 and Table 1),
consistent with the lack of HS6ST-1 expression in the
developing vasculature. The expression of HS6ST-1 in the
developing eyes and the central nervous system suggest that
HS6ST-1 may play a role in other biological functions
during development.
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example, leakiness of vessel walls and lumen patency),
microangiography was conducted on HS6ST-2 MO-injected
embryos using TRITC-dextran. Functional circulation was
observed in HS6ST-2 MO-injected embryos showing
reduced branching morphogenesis of the CV (Fig. 4D). Inthe most severe case, pooling of TRITC-dextran was
observed in the cavernous vessels that lack any branching
morphology (Fig. 4F).
To assess whether the defective morphogenesis of the
CV was specific to the loss of HS6ST-2 function, we
showed that two gene-specific morpholinos of independent
Fig. 3. Heparan sulfate disaccharide profiling of HS6ST-1 and HS6ST-2 morphant embryos. (A) Representative HPLC chromatograms of wild-type (black),
5 ng HS6ST-2 morpholino-injected (blue) and 2 ng HS6ST-1 morpholino-injected (red) embryos. Six disaccharides were identified: peak 1: DUA-GlcNAc,
D4,5 unsaturated hexuronate-N-acetyl glucosamine; peak 2: DUA-GlcNS, DUA-N-sulfated glucosamine; peak 3: DUA-GlcNAc6S, DUA-6-O-sulfated
GlcNAc; peak 4: DUA-GlcNS6S, DUA-6-O-sulfated GlcNS; peak 5: DUA2S-GlcNS, DUA2-O-sulfated GlcNS; peak 6: DUA2S-GlcNS6S. (B) Boxed region
of (A). Arrows represent the two 6-O sulfated disaccharides, peak 3 and peak 4, which are reduced in HS6ST-1 and HS6ST-2 morpholino-injected embryos.
(C) Graphical depiction of disaccharide composition in wild-type (black), HS6ST-2 (blue) and HS6ST-1 (red) morpholino-injected embryos, represented as
percent of total heparan sulfate. Inset is close up of peaks 3 and 4, DUA-GlcNAc6S and DUA-GlcNS6S, respectively. Asterisks indicate significant changes
from wild-type (t test P < 0.05 with HS6ST-1 peak 3 P < 0.001).
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including the formation of large loops in the plexus and
enlarged vascular channels (Fig. 4G). In contrast, injectionFig. 2. Embryonic expression patterns of zebrafish HS6ST-1 and HS6ST-2 mRN
HS6ST-2 is expressed in the forming somites (arrowheads in panels A–C). HS
arrowheads in C). (D) At 22-somite stage (20 hpf), zebrafish HS6ST-2 is expressed
of zebrafish HS6ST-2 is detected in the eyes, the brain and ventral medial somites
expression is detected in the ventral medial somites and cells surrounding the do
dashlines). The level of the section is indicated by the line in (E). (G) At 10-somite
neural tube (arrowheads). (H) At 16-somite stage, zebrafish HS6ST-1 is expressed
and the neural tube (arrowheads). (I) At 24 hpf, expression of zebrafish HS6ST-1
expression of zebrafish HS6ST-1 is detected in the diencephalon, the telencephalo
level of the dorsal rhombomeres (arrows). (K) Dorsal view of the embryo in (J), sh
Dorsal view, anterior to the top. (C, H) Lateral view, anterior to the bottom. (D–E
left. (K) Anterior to the left.of HS6ST-1 MO at a similar dose range did not generate a
significant percentage of embryos with caudal vein defects
(compare column 3 to columns 1 and 2 in Fig. 4G). WeA. (A) 4-somite stage. (B) 10-somite stage. (C) 16-somite stage. Zebrafish
6ST-2 expression is down-regulated in more differentiated somites (white
in a stripe of cells in somitic mesoderm (arrows). (E) At 24 hpf, expression
in the tail. (F) A transverse section of the embryo in (E). Zebrafish HS6ST-2
rsal aorta (A) and posterior cardinal vein (V) in the tail (as outlined by the
stage, zebrafish HS6ST-1 is expressed in the optic vesicles (arrow) and the
in the developing eyes (arrow), the tegmentum, the forming rhombomeres
is detected in the eyes (arrow), the brain and the neural tube. (J) At 33 hpf,
n, the tegmentum (arrowheads) and in four bilateral patches of cells at the
owing the four bilateral stripes of cells in the rhombomeres (arrows). (A–B)
, I – J) Lateral view, anterior to the left. (G) Lateral view, anterior to the top
Table 1
Quantification of heparan sulfate disaccharide profiles
Disaccharide pg HS/Ag protein % Change from wild-type
Wild-type Buffer HS6ST-2 MO HS6ST-1 MO HS6ST-2 MO HS6ST-1 MO
DUA-GlcNAc 6.4 T 0.5 7.2 T 0.3 5.7 T 0.3 6.1 T 0.5 12 T 7 8 T 2
DUA-GlcNS 2.4 T 0.1 2.3 T 0.3 2.1 T 0.1 2.5 T 0.1 13 T 5 +1 T 10
DUA-GlcNAc6S 0.44 T 0.04 0.53 T 0.01 0.32 T 0.03 0.28 T 0.01 28 T 4* 36 T 4*
DUA-GlcNS6S 0.75 T 0.06 0.78 T 0.05 0.57 T 0.05 0.55 T 0.03 24 T 8* 27 T 9*
DUA2S-GlcNS 2.25 T 0.09 2.4 T 0.5 2.0 T 0.1 2.4 T 0.2 10 T 5 +8 T 8
DUA2S-GlcNS6S 1.6 T 0.1 1.71 T 0.09 1.5 T 0.2 1.4 T 0.1 3 T 16 8 T 17
Total 14 T 1 14.9 T 0.2 12.27 T 0.07 13.18 T 0.04 12 T 7 6 T 7
Average pg HS/Ag protein from two individual experiments wild-type n = 7 samples, injected n = 4 samples. Each sample contains ¨100 embryos. TSEM.
* Values significantly different from wild-type ( P  0.05 t test).
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protein would alleviate the vascular defects observed in
HS6ST-2 MO-injected embryos. A mixed solution of
HS6ST-2 DNA expression construct that does not contain
the HS6ST-2 MO binding site and a DsRed construct was
co-injected with HS6ST-2 MO into Tg(fli-1:EGFP)
embryos. DsRed is introduced as a tracer to facilitate the
identification of DNA-injected embryos (Fig. 5D). In this
method, DNA injection results in the mosaic distribution
of inherited DNA in these embryos (Fig. 5D). Compared
to embryos injected with the HS6ST-2 MO alone, a higher
frequency of the co-injected embryos showed normal
formation of the caudal vein plexus (Fig. 5F, compare
the second column to the first columns, P < 0.0005). In
co-injected embryos, HS6ST-2-expressing cells correlated
with regions in the restored venous plexus (Fig. 5E). In
contrast, co-injection of a control expression construct did
not affect the frequency of vascular defects in HS6ST-2
MO-injected embryos (Fig. 5F, compare column 3 to
column 1, P > 0.2). These results indicate that the venous
defects observed in embryos injected with HS6ST-2 MO
are specific to the loss of HS6ST-2 function.
HS6ST-2 is required for somite development
A previous report by Bink et al. (2003) has demon-
strated that zebrafish HS6ST-2 plays a role during the late
stage of anterior somite patterning as indicated by the
reduced expression of mesp-b, a bHLH transcription factor
upstream of notch5 and notch6 in zebrafish, in HS6ST-2
morphant embryos. HS6ST-2 is also essential for proper
muscle differentiation. In wild-type embryos, high expres-
sion of myoD is only detected in posterior-most somites at
24 hpf. In contrast, myoD expression remains upregulated
in all somites of HS6ST-2 morphant embryos at 24 hpf
(Bink et al., 2003). We have also observed similar
alterations in the expression of mesp-b (34% T 7%, n =
49, TSEM) and myoD (67% T 17%, n = 46, TSEM),
supporting the role of HS6ST-2 in muscle development.
These noted defects in somitogenesis correlate with the
somitic wave of HS6ST-2 expression during segmentation
(Figs. 2A–E).Expression of late endothelial markers is reduced in
HS6ST-2 morphants
To assess the nature of the vascular defects in HS6ST-2
morphants, in situ hybridization was conducted to analyze
expression of endothelial markers in HS6ST-2 morphants
during vascular development. Expression of flk-1, which
encodes a Vascular Endothelial Growth Factor (VEGF)
receptor, is first detected in bilateral stripes of endothelial
precursor cells during early somitogenesis and becomes
localized to the endothelium of developing blood vessels
from late somitogenesis to about 36 hpf (Fouquet et al.,
1997). Compared to uninjected wild-type embryos, flk-1
expression was normal in HS6ST-2 morphants at 24 hpf
(Fig. 6B), indicating that the primary formation of the axial
vessels and initial sprouting of intersegmental vessels
proceed normally in HS6ST-2 morphants.
In a zebrafish embryo, branches from the developing
caudal vein are observed at 30 hpf and form a plexus up to
40 hpf. The caudal vein is subsequently remodeled to form a
single vascular tube by day 5 post-fertilization (Isogai et al.,
2001; Huang et al., 2003). The vascular markers, tie-1 and
tie-2, are expressed in the endothelium of the vasculature
undergoing this angiogenic remodeling process (Lyons et
al., 1998). Expression domains of tie-1 and tie-2 were
reduced in the developing caudal vein of HS6ST-2 MO-
injected embryos at 30 hpf (arrowheads in Fig. 6D and data
not shown; compare to uninjected control, Fig. 6C) and at
48 hpf (data not shown). These results indicate that the
venous defects observed in HS6ST-2 morphants occur
during latter stages of vascular development in zebrafish
embryos.
HS6ST-2 and VEGF interact in vivo during caudal vein
plexus formation
VEGF-A is one of several heparin-binding growth
factors that play an essential role in angiogenesis. To assess
for an in vivo interaction between HS6ST-2 and VEGF-A
during caudal vein plexus formation, morpholinos against
HS6ST-2 and VEGF-A were co-injected into embryos using
doses that alone elicited only minimal effects on venous
Fig. 4. Zebrafish HS6ST-2 is essential for branching morphogenesis of the caudal vein in zebrafish embryos. (A) Tg(fli-1:EGFP) embryo at 48 hpf under FITC
illumination with inset at the lower left corner showing a region of the venous plexus. (B) Angiogram of the Tg(fli-1:EGFP) embryo in (A) under TRITC
illumination. (C–D) Tg(fli-1:EGFP) embryo injected with 5 ng of HS6ST-2 MO2 (C) and the angiogram of the same embryo (D) showing reduced branching
as indicated by large loops (arrowheads) in the caudal vein plexus. (E–F) In the more severe case, the venous plexus in a Tg(fli-1:EGFP) embryo fails to
achieve the complexity as observed in Tg(fli-1:EGFP) embryos. Instead, the formation of a cavernous vessel (arrowheads) is observed. (G) A summary graph
showing results of injections using two non-overlapping morpholinos against the zebrafish HS6ST-2 gene. Both oligos generate similar cardinal vein defects
including formation of large loops and cavernous vessels with high penetrance. In contrast, HS6ST-1 MO (column 3) does not generate a significant percentage
of embryos with CV defects. CV, cardinal vein. N denotes the number of embryos analyzed. TSEM. The lines in panels A, C and E indicate the segments of
venous plexus displayed in insets.
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injection of either HS6ST-2 MO or VEGF-A MO alone, co-
injection of HS6ST-2 MO and VEGF-A MO resulted in
synergistic increase in the frequency of embryos with caudalvein branching defects, i.e., formation of large loops and
cavernous vessels (Fig. 7F, column 3; see examples in Figs.
7D–E). Co-injection of HS6ST-2 MO and a four-base
mismatch VEGF-A MO (d4) abolished the synergy (Fig. 7F,
Fig. 5. Co-injection of zebrafish HS6ST-2 expression construct alleviates the caudal vein defects in HS6ST-2 morphant embryos. (A) Uninjected
Tg(fli-1:EGFP) embryo at 33 hpf under FITC illumination. (B) HS6ST-2 MO2-injected embryo with defective caudal vein branching as indicated by the
formation of a cavernous vessel (arrows). (C) Embryo co-injected with HS6ST-2 MO2 and a mixed solution of HS6ST-2 DNA and DsRed DNA, showing the
restoration of the venous plexus (arrows) under FITC illumination. DsRed is introduced as a tracer to facilitate the identification of DNA-injected embryos. (D)
DsRed expression in the same co-injected embryo showing mosaic expression pattern in the tail under TRITC illumination. (E) Overlay of panels C and D,
showing DsRed expressing-cells, correlating with areas in the restored venous plexus (arrowheads). (F) Summary of four independent co-injection experiments.
The test DNA (HS6ST-2 expression construct) or the control DNA (DsRed expression construct) was injected into embryos separately injected with HS6ST-2
MO2. The introduction of HS6ST-2 protein by the DNA injection alleviates the caudal vein defects in HS6ST-2 MO2-injected embryos (compare column 2 to
column 1). Asterisk (*) denotes statistical significance with P < 0.0005. In contrast, a separate injection of control DNA into HS6ST-2 MO2-injected embryos
does not affect the frequency of caudal vein defects in HS6ST-2MO2-injected embryos (compare column 3 to column 1; P > 0.2). N indicates the total number of
embryos scored. TSEM.
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A interact in vivo during caudal vein formation.Discussion
The specific sulfation pattern of heparan sulfate is
essential for its ability to interact with a variety of heparin-
binding growth factors involved in angiogenesis. While 6-
O sulfation has been implicated in vessel formation in
vitro (Lundin et al., 2000), the in vivo function of 6-O
sulfation in vascular development is poorly understood. In
this study, we have used zebrafish as a vertebrate model
system to understand the role of 6-O sulfation in vascular
development. We have examined the function of two
HS6ST genes, HS6ST-1 and HS6ST-2. Structural analyses
of heparan sulfate disaccharides isolated from HS6ST-1
and HS6ST-2 morphants indicated that these two enzymesare required for the normal 6-O sulfation pattern of
heparan sulfate. HS6ST-1 and HS6ST-2 display distinct
expression patterns. HS6ST-2 is expressed in the region of
the developing caudal vein and is required for the
branching morphogenesis of the caudal vein. This study
provides the first in vivo evidence of a heparan sulfate
modifying gene, HS6ST-2, being essential for vascular
development.
Distinct expression patterns and functions for HS6ST-1 and
HS6ST-2
In situ hybridization revealed dynamic, highly localized
expression patterns of HS6ST-1 and HS6ST-2 during
development. The expression of HS6ST-2 in the cells
surrounding the dorsal aorta and posterior cardinal vein
suggested that it might have a role in vascular develop-
ment or function. This was substantiated by the reduced
Fig. 6. Expression of late endothelial markers in the region of forming venous plexus is reduced in HS6ST-2 morphants. Expression of flk-1 as shown by
whole-mount in situ hybridization in a wild-type embryo (A) and a HS6ST-2 MO-injected embryo (B) at 24 hpf. Normal expression of flk-1 is observed in
HS6ST-2 MO-injected embryos at 24 hpf (n = 19). However, at 30 hpf, the expression domain of the late endothelial marker, tie-1 (D; 81% T 8%, n = 40,
TSEM) is reduced in the region of caudal vein (area indicated by brackets and arrowheads) in HS6ST-2 MO-injected embryos compared to wild-type
embryos (C).
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in HS6ST-2 morphants. Our analysis of HS6ST-2 expres-
sion in the developing somites also supports a role in
muscle development, as previously proposed (Bink et al.,
2003). In contrast, morpholino knockdown of HS6ST-1 did
not affect vascular development, and its expression pattern
indicates that it may be important for eye and brain
development.
Compositional analysis of heparan sulfate from HS6ST
morpholino antisense knockdown embryos
Biochemical analysis of heparan sulfate from mor-
phant embryos demonstrated that both HS6ST-1 and
HS6ST-2 affect 6-O-sulfation of both N-sulfoglucos-
amine and N-acetyl glucosamine. In contrast, cell free
assays of HS6STs (Habuchi et al., 2000, 2003; Bink et
al., 2003) suggested that these enzymes exhibit poor
activity towards N-acetyl glucosamine (Habuchi et al.,
2000). Similarly Bink et al. (2003) observed very little
sulfation of N-acetyl glucosamine by zebrafish HS6ST-2
extracted from COS-7 cells. In vivo analysis, however,
from our study and that of Bink et al. (2003) suggest
that HS6STs can affect 6-O sulfation of N-acetyl glu-
cosamine. Compared to Bink et al. (2003), we noted
less of a decrease in the disaccharide DUA-GlcNS6S
and no significant decrease in DUA2S-GlcNS6S upon
morpholino knockdown of HS6ST-2, perhaps due to our
use of only one of the two morpholino sequences they
used or to possible strain/staging specific differences in
the wild-type disaccharide profiles. Interestingly, in both
studies, the level of DUA2S-GlcNS6S, found to be cri-
tical for heparan sulfate binding of a number of proteins(Feyzi et al., 1997; Parthasarathy et al., 1994), was
preserved to a greater extent than the other 6-O-sulfated
disaccharides in the morphant embryos. This may
represent a mechanism to retain specific ligand binding
properties of heparan sulfate at low enzyme levels. It is
likely that the recognition site for the HS6STs in vivo is
more complex than the individual substrate disaccharide
type, and its activity depends on the surrounding
sequence having the correct structural features (Zhang
et al., 2001, Smeds et al., 2003, Jemth et al., 2003).
Although we were not able to detect disaccharide type
specificity for zebrafish HS6ST-1 and HS6ST-2, their
substrate recognition sites may be unique to the heparan
sulfate of the separate tissues in which they are ex-
pressed. Our results suggest that the tissue-specific expres-
sion of the HS6STs may contribute to their unique
biological functions.
Analysis of the role of HS6ST-2 in angiogenesis
In this study, the role of HS6ST-2 in angiogenesis is
explored. As the primary vasculature is laid down in a
vertebrate embryo, the primitive network of blood vessels
undergoes a series of remodeling steps to form mature
vasculature, which is further stabilized by the recruitment of
smooth muscle cells and other supporting cells (Carmeliet,
2000). Reduced expression domains of the late endothelial
markers tie-1 and tie-2 in the caudal vein during the time
period of remodeling indicate that HS6ST-2 is important for
development of the vasculature in this region. This result
correlates with the reduced branching complexity of the
caudal vein plexus observed in the HS6ST-2 morphant
Tg(fli-1:EGFP) embryos and the location of HS6ST-2
Fig. 7. HS6ST-2 and VEGF-A interact during caudal vein plexus formation in vivo. (A) Uninjected Tg(fli-1:EGFP) embryo at 33 hpf under FITC channel, with
the inset displaying an enlargement of a segment in the venous plexus. (B) Embryo injected with 0.5 ng of HS6ST-2 MO2 displaying a venous plexus without
any obvious defect. (C) Embryo injected with 1 ng of VEGF-A MO, displaying a venous plexus without any obvious defect. (D–E) Embryo co-injected with
HS6ST-2 MO2 and VEGF-A MO displaying defective branching morphogenesis of the venous plexus as indicated by the formation of large loops (arrowheads
in inset of D) and a single cavernous vessel with no branching (arrowheads in inset of E). The lines in A, D and E indicate regions in the venous plexus that are
displayed in the insets. (F) A summary of two independent experiments is shown. Embryos co-injected with HS6ST-2 MO2 (0.5 ng) and VEGF-A MO (1 ng)
exhibit a more than additive increase in the frequency (TSEM) of embryos with branching defects in the caudal vein plexus (column 3) compared to embryos
injected with HS6ST-2 MO2 or VEGF-A MO only. In contrast, no synergy is observed in the embryos co-injected with HS6ST-2 MO and a four-base mismatch
MO (d4, 1 ng) against VEGF-A (column 4).
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The caudal vein plexus is a paradigm for studying the
complexity of vertebrate angiogenesis because first it
expands and then is gradually remodeled to form a single
vascular tube (Isogai et al., 2001). The caudal vein
phenotype we observed in the HS6ST-2 morphants is
similar to that of reg6 zebrafish mutants, which also display
defects in the branching morphogenesis of the caudal vein
(Huang et al., 2003). This suggests that HS6ST-2 plays an
essential role in the remodeling process of the caudal vein
plexus. However, we cannot exclude the possibility that
defective muscle differentiation in HS6ST-2 morphantembryos may contribute to the defects of the venous plexus
observed.
Role of HS6STs in branching morphogenesis
A number of studies have also provided evidence that
6-O-sulfated heparan sulfate may be important for the pre-
cise localization and activity of secreted modulators of
branching morphogenesis. HS6STs are necessary for FGF-
dependent branching morphogenesis in the Drosophila
tracheal system and the mammalian lung (Kamimura et al.,
2001; Izvolsky et al., 2003). In both cases, 6-O-sulfation is
E. Chen et al. / Developmental Biology 284 (2005) 364–376 375predominantly in the FGF target cells, supporting its
proposed requirement for FGFR activation (Pye et al.,
1998; Ostrovsky et al., 2002). Spatial and temporal variance
of heparan sulfate structure has been shown to facilitate
assembly of specific FGF–FGFR pairs (Allen and Rap-
raeger, 2003). Normal vascular branch formation requires the
heparin-binding sites of VEGF-A, (Ruhrberg et al., 2002),
another ligand of 6-O-sulfated heparan sulfate (Ono et al.,
1999). The ability to bind heparan sulfate has been shown to
be necessary to spatially restrict VEGF to regulate vascular
branching pattern (Ruhrberg et al., 2002).
We have observed a synergy between the HS6ST-2 MO
and the VEGF-A MO in generating embryos with defective
branching in the caudal vein, suggesting that HS6ST-2 and
VEGF-A interact during angiogenesis in vivo. As HS6ST-2
is expressed in the cells surrounding the caudal vein plexus,
it is possible that the changes in the heparan sulfate
modifications on the cell surface or in the extracellular
matrix, induced by HS6ST-2, influence VEGF signaling by
modulating the bioavailability of VEGF in the regions of the
venous plexus. Another possibility is that the changes in the
heparan sulfate profile induced by HS6ST-2 affect the
signaling activity of other heparin-binding growth factors
and in turn influence VEGF-mediated signaling. It remains
to be investigated whether HS6ST-2 expression in the
caudal vein plexus is important for regulating the activity of
FGF or one of the many other ligands of heparan sulfate
(Esko and Selleck, 2002).
In conclusion, we have demonstrated that HS6ST-1 and
HS6ST-2 display distinct expression profiles and that
HS6ST-2 has a unique role in vascular development.
Previous in vivo studies have shown diverse roles for
specific sulfate modifications of heparan sulfate in a variety
of biological processes including axon guidance (Bulow and
Hobert, 2004) and kidney development (Bullock et al.,
1998). The results described here support the hypothesis
that regulation of the sulfation pattern of heparan sulfate is a
fine control mechanism of many physiological processes.
Our finding that HS6ST-2 is essential for the branching
morphogenesis of the caudal vein is the first in vivo
evidence for a role of a specific heparan sulfate modifying
enzyme in vertebrate angiogenesis. This result advocates the
therapeutic benefit of agents controlling heparan sulfate
modification to ameliorate a number of disorders that
involve pathological angiogenesis, including tumor growth,
diabetic retinopathy and coronary heart disease.Acknowledgments
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